drugset / Trial / NCT05627414
Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II, one-arm study, which is aiming to evaluate the feasibility of combination of Disitamab Vedotin, Sintilimab and S-1 as conversion therapy in patients with HER2 overexpression unresectable gastric cancer .
Timeline
- Start
- 2023-01-01
- Primary completion
- 2024-06-01
- Completion
- 2025-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Disitamab Vedotin | Monoclonal antibody | 2.5 mg/kg | Intravenous |
| Subject | S-1 | Small molecule | 40 mg/m2 | — |
| Subject | S-1 | Small molecule | 60 mg/m2 | — |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |